Global Atrial Fibrillation Market Report: 2011 Edition
Atrial Fibrillation continues to be the most common heart rhythm disorders ailing the modern society. The incidence and prevalence of atrial fibrillation is on the rise worldwide, mainly due to changes in demographic and lifestyle patterns. This has led to increased consumption of the related drugs and devices which is reflected in the continuous growth of the global atrial fibrillation market as also forecasted by the industry experts. The US and Europe are the two major regions where atrial fibrillation is the most common sustained heart rhythm disorder prevailing among masses and as observed in clinical practice.
The continuous introduction and uptake of new anticoagulants in the atrial fibrillation market and the medical fraternity’s growing support to their increased usage are two major trends being observed in the global atrial fibrillation market. Modern research has produced new hybrid treatment procedures and innovative ablation catheters for the management of atrial fibrillation. Such new products and researches are a development affecting the growth of the atrial fibrillation market all across the globe. Furthermore, improved product and treatment efficacy due to continuous research and development has resulted in their increased adoption by doctors and patients alike. Another major factor driving the growth of the global atrial fibrillation market is the increasing number of elderly and diabetic patients worldwide.
The global atrial fibrillation market is highly competitive with numerous small and large companies located throughout the world. The leading players of the market include St. Jude Medical, Boston Scientific Corporation, Johnson & Johnson's Biosense Webster, C. R. Bard, Medtronic, and Atricure, among others. As the market is characterized by rapid technological advancements, competition in research involving improvement of new and existing products and processes is particularly significant.
The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.
The continuous introduction and uptake of new anticoagulants in the atrial fibrillation market and the medical fraternity’s growing support to their increased usage are two major trends being observed in the global atrial fibrillation market. Modern research has produced new hybrid treatment procedures and innovative ablation catheters for the management of atrial fibrillation. Such new products and researches are a development affecting the growth of the atrial fibrillation market all across the globe. Furthermore, improved product and treatment efficacy due to continuous research and development has resulted in their increased adoption by doctors and patients alike. Another major factor driving the growth of the global atrial fibrillation market is the increasing number of elderly and diabetic patients worldwide.
The global atrial fibrillation market is highly competitive with numerous small and large companies located throughout the world. The leading players of the market include St. Jude Medical, Boston Scientific Corporation, Johnson & Johnson's Biosense Webster, C. R. Bard, Medtronic, and Atricure, among others. As the market is characterized by rapid technological advancements, competition in research involving improvement of new and existing products and processes is particularly significant.
The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.
1. HEPATITIS C VIRUS (HCV) MARKET OVERVIEW
1.1 HCV Market: Introduction
1.2 HCV Market Size
1.2.1 Global HCV Market
2. REGIONAL ANALYSIS
2.1 North America
2.2 Western Europe
2.3 North Africa & Middle East
2.4 Eastern Europe & Central Europe
2.5 Sub & Sahara African Region
2.6 South & South East Asia
2.7 East Asia & Pacific
2.8 Australia & New Zealand
2.9 Latin America & Caribbean
3. HEPATITIS C VIRUS (HCV): DIAGNOSIS MARKET
3.1 Hepatitis C Virus Diagnosis: Introduction
3.2 Hepatitis C Virus Diagnosis: Market Size
4. HEPATITIS C VIRUS (HCV): TREATMENT MARKET
4.1 Hepatitis C Virus (HCV) Treatment Market: Introduction
4.2 Hepatitis C Virus (HCV) Treatment: Market Size
4.3 Hepatitis C Virus (HCV) Drugs Market
5. MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Growing Worldwide Population
5.1.2 Rise in number of drug addicts
5.2 Key Issues
5.2.1 Lesser percentage of survival in obese and diabetic HCV patients
5.2.2 Rising HCV treatment Cost
5.2.3 Lesser availability of insurers in HCV
5.3 Market Trends
5.3.1 Advancement in new drugs
5.3.2 Paradigm shift to HCV herbal supplement
6. COMPETITIVE LANDSCAPE
6.1 Roche Pharmaceutical
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck Pharmaceutical
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Vertex Pharmaceutical
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
7. MARKET OUTLOOK
7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
1.1 HCV Market: Introduction
1.2 HCV Market Size
1.2.1 Global HCV Market
2. REGIONAL ANALYSIS
2.1 North America
2.2 Western Europe
2.3 North Africa & Middle East
2.4 Eastern Europe & Central Europe
2.5 Sub & Sahara African Region
2.6 South & South East Asia
2.7 East Asia & Pacific
2.8 Australia & New Zealand
2.9 Latin America & Caribbean
3. HEPATITIS C VIRUS (HCV): DIAGNOSIS MARKET
3.1 Hepatitis C Virus Diagnosis: Introduction
3.2 Hepatitis C Virus Diagnosis: Market Size
4. HEPATITIS C VIRUS (HCV): TREATMENT MARKET
4.1 Hepatitis C Virus (HCV) Treatment Market: Introduction
4.2 Hepatitis C Virus (HCV) Treatment: Market Size
4.3 Hepatitis C Virus (HCV) Drugs Market
5. MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Growing Worldwide Population
5.1.2 Rise in number of drug addicts
5.2 Key Issues
5.2.1 Lesser percentage of survival in obese and diabetic HCV patients
5.2.2 Rising HCV treatment Cost
5.2.3 Lesser availability of insurers in HCV
5.3 Market Trends
5.3.1 Advancement in new drugs
5.3.2 Paradigm shift to HCV herbal supplement
6. COMPETITIVE LANDSCAPE
6.1 Roche Pharmaceutical
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck Pharmaceutical
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Vertex Pharmaceutical
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
7. MARKET OUTLOOK
7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
LIST OF CHARTS & TABLES
Risk Factors for infection with Hepatitis C Virus
New HCV Cases Registered Globally, 2005-2010
HCV Infection Rate Reported in Male & Female Globally, 2005-2009
HCV Infection Rate Reported by Age-Group & Gender Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Females Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Males Globally, 2005-2009
Acute & Chronic HCV Infection Rate Registered Globally, 2005-2009
Percentage Breakup of New HCV Cases by Geography, 2010
New HCV Cases Registered in North America, 2005-2010
New HCV Cases Registered by Age Group in North America, 2010
New HCV Cases Registered in Western Europe, 2005-2010
Hepatitis C Virus infected by Race & Ethnicity in Western Europe, 2010
New HCV Cases Registered in North Africa & Middle East, 2005-2010
New HCV Cases Registered in Eastern & Central Europe, 2005-2010
New HCV Cases Registered in Sub & Sahara African Region, 2005-2010
New HCV Cases Registered in South & South East Asia, 2005-2010
New HCV Cases Registered in East Asia & Pacific, 2005-2010
New HCV Cases Registered in Australia & New Zealand, 2005-2010
New HCV Cases Registered in Latin America & Caribbean, 2005-2010
Percentage Detection of Anti-HCV antibodies in Patients
Patients Infected with HCV Genotypes Globally, 2010
HCV Patients Segmentation Globally, 2010
Number of HCV Patients Diagnosed Globally, 2008–2015F
Number of HCV Patients Diagnosed by Race Globally, 2009
Number of HCV Patients Diagnosed by Age Group Globally, 2010
Number of Patients Provided with Interferon (IFN) Therapy in the US, 2000-2010
PEG-Interferon (IFN)/Ribavirin Therapy Access to different Patient segments Globally, 2010
Number of HCV Patients Underwent Treatment Globally, 2007–2015F
Worldwide HCV Drugs Market Size by Value, 2006–2010
The US HCV Drugs Market Size by Value, 2009–2012F
Worldwide Population (2006-2013F)
Number of Drug Addicts Underwent HCV Treatment (2006-2013F)
Survival rates in HCV Patients Suffering from Diabetes and Obesity, 2010
HCV Treatment Cost, 2008-2010
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Global HCV Drugs Market Forecast 2010-2014F
Response Rates of Treatment in Patients
Treatment Approach will Change Significantly until 2015
Worldwide Sales Estimates for Telaprevir & Boceprevir (US$ millions)
Dependent & Independent Variables (2006–2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Risk Factors for infection with Hepatitis C Virus
New HCV Cases Registered Globally, 2005-2010
HCV Infection Rate Reported in Male & Female Globally, 2005-2009
HCV Infection Rate Reported by Age-Group & Gender Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Females Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Males Globally, 2005-2009
Acute & Chronic HCV Infection Rate Registered Globally, 2005-2009
Percentage Breakup of New HCV Cases by Geography, 2010
New HCV Cases Registered in North America, 2005-2010
New HCV Cases Registered by Age Group in North America, 2010
New HCV Cases Registered in Western Europe, 2005-2010
Hepatitis C Virus infected by Race & Ethnicity in Western Europe, 2010
New HCV Cases Registered in North Africa & Middle East, 2005-2010
New HCV Cases Registered in Eastern & Central Europe, 2005-2010
New HCV Cases Registered in Sub & Sahara African Region, 2005-2010
New HCV Cases Registered in South & South East Asia, 2005-2010
New HCV Cases Registered in East Asia & Pacific, 2005-2010
New HCV Cases Registered in Australia & New Zealand, 2005-2010
New HCV Cases Registered in Latin America & Caribbean, 2005-2010
Percentage Detection of Anti-HCV antibodies in Patients
Patients Infected with HCV Genotypes Globally, 2010
HCV Patients Segmentation Globally, 2010
Number of HCV Patients Diagnosed Globally, 2008–2015F
Number of HCV Patients Diagnosed by Race Globally, 2009
Number of HCV Patients Diagnosed by Age Group Globally, 2010
Number of Patients Provided with Interferon (IFN) Therapy in the US, 2000-2010
PEG-Interferon (IFN)/Ribavirin Therapy Access to different Patient segments Globally, 2010
Number of HCV Patients Underwent Treatment Globally, 2007–2015F
Worldwide HCV Drugs Market Size by Value, 2006–2010
The US HCV Drugs Market Size by Value, 2009–2012F
Worldwide Population (2006-2013F)
Number of Drug Addicts Underwent HCV Treatment (2006-2013F)
Survival rates in HCV Patients Suffering from Diabetes and Obesity, 2010
HCV Treatment Cost, 2008-2010
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Global HCV Drugs Market Forecast 2010-2014F
Response Rates of Treatment in Patients
Treatment Approach will Change Significantly until 2015
Worldwide Sales Estimates for Telaprevir & Boceprevir (US$ millions)
Dependent & Independent Variables (2006–2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
